Potential role of daratumumab in the treatment of multiple myeloma

por Khagi, Yulian, Mark, Tomer M
Publicado 2014

Clinical Management of Triple-Class Refractory Multiple Myeloma: A Review of Current Strategies and Emerging Therapies

por Stalker, Margaret E., Mark, Tomer M.
Publicado 2022

Impacting T-cell fitness in multiple myeloma: potential roles for selinexor and XPO1 inhibitors

por Binder, Adam F., Walker, Christopher J., Mark, Tomer M., Baljevic, Muhamed
Publicado 2023

Lenalidomide‐induced autoimmune enteropathy complicating treatment of multiple myeloma with concurrent systemic mastocytosis

por Lakritz, Stephanie, Forsberg, Peter A., Sherbenou, Daniel W., Mark, Tomer M.
Publicado 2022

Harnessing the T Cell to Treat Multiple Myeloma: Dawn of a New Therapeutic Paradigm

por Keller, Alana L., Sherbenou, Daniel W., Forsberg, Peter A., Mark, Tomer M.
Publicado 2022

Diaphragmatic Amyloidosis Causing Respiratory Failure: A Case Report and Review of Literature

por Novikov, Aleksey, Holzer, Horatio, DeSimone, Robert A., Abu-Zeinah, Ghaith, Pisapia, David J., Mark, Tomer M., Pastore, Raymond D.
Publicado 2015

309 MYC Inhibition Overcomes IMiD Resistance in Heterogeneous Multiple Myeloma Populations

por Davis, Lorraine, Walker, Zachary J., Ohlstrom, Denis, Stevens, Brett M., Forsberg, Peter A., Mark, Tomer M., Jordan, Craig T., Sherbenou, Daniel W.
Publicado 2022

CD46–ADC Reduces the Engraftment of Multiple Myeloma Patient-Derived Xenografts

por VanWyngarden, Michael J., Walker, Zachary J., Su, Yang, Perez de Acha, Olivia, Stevens, Brett M., Forsberg, Peter A., Mark, Tomer M., Matsui, William, Liu, Bin, Sherbenou, Daniel W.
Publicado 2023

Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma

por Chari, Ajai, Lonial, Sagar, Mark, Tomer M., Krishnan, Amrita Y., Stockerl‐Goldstein, Keith E., Usmani, Saad Z., Londhe, Anil, Etheredge, Delores, Fleming, Sarah, Liu, Baolian, Ukropec, Jon, Lin, Thomas S., Jagannath, Sundar, Nooka, Ajay K.
Publicado 2018

CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies

por Perez de Acha, Olivia, Reiman, Lauren, Jayabalan, David S., Walker, Zachary J., Bosma, Grace, Keller, Alana L., Parzych, Sarah E., Abbott, Diana, Idler, Beau M., Ribadeneyra, Drew, Niesvizky, Ruben, Forsberg, Peter A., Mark, Tomer M., Sherbenou, Daniel W.
Publicado 2023

Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial

por Sonneveld, Pieter, Chanan-Khan, Asher, Weisel, Katja, Nooka, Ajay K., Masszi, Tamas, Beksac, Meral, Spicka, Ivan, Hungria, Vania, Munder, Markus, Mateos, Maria-Victoria, Mark, Tomer M., Levin, Mark-David, Ahmadi, Tahamtan, Qin, Xiang, Garvin Mayo, Wendy, Gai, Xue, Carey, Jodi, Carson, Robin, Spencer, Andrew
Publicado 2023

Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk

por Weisel, Katja, Spencer, Andrew, Lentzsch, Suzanne, Avet-Loiseau, Hervé, Mark, Tomer M., Spicka, Ivan, Masszi, Tamas, Lauri, Birgitta, Levin, Mark-David, Bosi, Alberto, Hungria, Vania, Cavo, Michele, Lee, Je-Jung, Nooka, Ajay, Quach, Hang, Munder, Markus, Lee, Cindy, Barreto, Wolney, Corradini, Paolo, Min, Chang-Ki, Chanan-Khan, Asher A., Horvath, Noemi, Capra, Marcelo, Beksac, Meral, Ovilla, Roberto, Jo, Jae-Cheol, Shin, Ho-Jin, Sonneveld, Pieter, Casneuf, Tineke, DeAngelis, Nikki, Amin, Himal, Ukropec, Jon, Kobos, Rachel, Mateos, Maria-Victoria
Publicado 2020

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR

por Spencer, Andrew, Lentzsch, Suzanne, Weisel, Katja, Avet-Loiseau, Hervé, Mark, Tomer M., Spicka, Ivan, Masszi, Tamas, Lauri, Birgitta, Levin, Mark-David, Bosi, Alberto, Hungria, Vania, Cavo, Michele, Lee, Je-Jung, Nooka, Ajay K., Quach, Hang, Lee, Cindy, Barreto, Wolney, Corradini, Paolo, Min, Chang-Ki, Scott, Emma C., Chanan-Khan, Asher A., Horvath, Noemi, Capra, Marcelo, Beksac, Meral, Ovilla, Roberto, Jo, Jae-Cheol, Shin, Ho-Jin, Sonneveld, Pieter, Soong, David, Casneuf, Tineke, Chiu, Christopher, Amin, Himal, Qi, Ming, Thiyagarajah, Piruntha, Sasser, A. Kate, Schecter, Jordan M., Mateos, Maria-Victoria
Publicado 2018

Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation

por Uy, Geoffrey L., Costa, Luciano J., Hari, Parameswaran N., Zhang, Mei-Jie, Huang, Jia-Xing, Anderson, Kenneth C., Bredeson, Christopher N., Callander, Natalie S., Cornell, Robert Frank, Perez, Miguel Angel Diaz, Dispenzieri, Angela, Freytes, César O., Gale, Robert Peter, Garfall, Alfred, Gertz, Morie A., Gibson, John, Hamadani, Mehdi, Lazarus, Hillard M., Kalaycio, Matt E., Kamble, Rammurti T., Kharfan-Dabaja, Mohamed A., Krishnan, Amrita Y., Kumar, Shaji K., Kyle, Robert A., Landau, Heather J., Lee, Cindy H., Maiolino, Angelo, Marks, David I., Mark, Tomer M., Munker, Reinhold, Nishihori, Taiga, Olsson, Richard F., Ramanathan, Muthalagu, Rodriguez, Tulio E., Saad, Ayman A., Savani, Bipin N., Schiller, Gary J., Schouten, Harry C., Schriber, Jeffrey R., Scott, Emma, Seo, Sachiko, Sharma, Manish, Ganguly, Siddhartha, Stadtmauer, Edward A., Tay, Jason, To, L. Bik, Vesole, David H., Vogl, Dan T., Wagner, John L., Wirk, Baldeep, Wood, William A., D’Souza, Anita
Publicado 2015